Retatrutide has emerged as a new treatment in the fight against obesity. This revolutionary drug, classified as a dual GLP-1 and GIP receptor agonist, shows promising results in investigations. By boosting these receptors, Retatrutide suppresses appetite, {promotesinsulin secretion, and ultimately leads to significant reduction in body mass. While